Novonesis (Novozymes) B (FRA:NZM) Cyclically Adjusted Book per Share: €9.54 (As of Mar. 2026)


FRA:NZM Novonesis (Novozymes) B FRA:NZM
91 GF Score
Price €55.50
GF Value €55.83
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Cyclically Adjusted Book per Share?

Novonesis (Novozymes) B FRA:NZM +0.91% 91 Cyclically Adjusted Book per Share is €9.54 as of Mar. 2026. GuruFocus rates FRA:NZM with a GF Score™ of 91/100 and a GF Value™ of €55.83 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novonesis (Novozymes) B's adjusted book value per share for the three months ended in Mar. 2026 was €23.421. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €9.54 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novonesis (Novozymes) B's average Cyclically Adjusted Book Growth Rate was 24.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 15.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novonesis (Novozymes) B was 15.00% per year. The lowest was 4.60% per year. And the median was 7.15% per year.

As of today (2026-07-11), Novonesis (Novozymes) B's current stock price is €55.50. Novonesis (Novozymes) B's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €9.54. Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio of today is 5.82.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novonesis (Novozymes) B was 13.63. The lowest was 5.20. And the median was 9.23.


Novonesis (Novozymes) B  (FRA:NZM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=55.50/9.54
=5.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novonesis (Novozymes) B was 13.63. The lowest was 5.20. And the median was 9.23.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novonesis (Novozymes) B Cyclically Adjusted Book per Share Related Terms


Novonesis (Novozymes) B Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Cyclically Adjusted Book per Share Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.19 5.82 5.98 6.94 8.80

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.40 8.14 8.22 8.80 9.54

FRA:NZM vs LIN, SHW, ECL: Cyclically Adjusted Book per Share Comparison

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B Cyclically Adjusted PB Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio falls into.


FRA:NZM
91GF Score
Novonesis (Novozymes) B FRA:NZM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novonesis (Novozymes) B's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=23.421/121.6800*121.6800
=23.421

Current CPI (Mar. 2026) = 121.6800.

Novonesis (Novozymes) B Quarterly Data

Book Value per Share CPI Adj_Book
201606 4.899 100.600 5.926
201609 4.925 100.200 5.981
201612 5.304 100.300 6.435
201703 4.952 101.200 5.954
201706 4.857 101.200 5.840
201709 4.924 101.800 5.886
201712 5.160 101.300 6.198
201803 4.690 101.700 5.611
201806 4.946 102.300 5.883
201809 5.075 102.400 6.031
201812 5.320 102.100 6.340
201903 5.078 102.900 6.005
201906 5.170 102.900 6.114
201909 5.292 102.900 6.258
201912 5.456 102.900 6.452
202003 5.110 103.300 6.019
202006 5.171 103.200 6.097
202009 5.196 103.500 6.109
202012 5.404 103.400 6.359
202103 5.192 104.300 6.057
202106 5.284 105.000 6.123
202109 5.617 105.800 6.460
202112 5.739 106.600 6.551
202203 5.484 109.900 6.072
202206 5.885 113.600 6.304
202209 6.644 116.400 6.945
202212 6.714 115.900 7.049
202303 6.251 117.300 6.484
202306 6.489 116.400 6.783
202309 6.995 117.400 7.250
202312 6.763 116.700 7.052
202403 0.000 118.400 0.000
202406 23.696 118.500 24.332
202409 0.000 118.900 0.000
202412 23.976 118.900 24.537
202503 24.090 120.200 24.387
202506 23.073 120.700 23.260
202509 23.072 121.600 23.087
202512 23.299 121.200 23.391
202603 23.421 121.680 23.421

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €9.54 mean?
Novonesis (Novozymes) B (FRA:NZM) has a Cyclically Adjusted Book per Share of €9.54 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Cyclically Adjusted Book per Share too high?
Novonesis (Novozymes) B's current Cyclically Adjusted Book per Share is €9.54. Overall, Novonesis (Novozymes) B has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Cyclically Adjusted Book per Share compare to LIN and SHW?
Novonesis (Novozymes) B's Cyclically Adjusted Book per Share of €9.54 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Chemicals company?
A good Cyclically Adjusted Book per Share depends on the Chemicals industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Cyclically Adjusted Book per Share is €9.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (FRA:NZM) is currently considered Fairly Valued. The stock's GF Value™ is €55.83, compared to a current price of €55.50 — trading 0.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is €9.54. Novonesis (Novozymes) B's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novonesis (Novozymes) B (FRA:NZM), the current Cyclically Adjusted Book per Share is €9.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (FRA:NZM) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued. The current stock price of €55.50 is trading 0.6% below its estimated GF Value™ of €55.83. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for FRA:NZM:

  • Cyclically Adjusted Book per Share: €9.54
  • GF Value™: €55.83 vs. price of €55.50 (0.6% below fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the FRA:NZM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score

Get the complete analysis for FRA:NZM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.50
Price
€55.83
GF Value